| 陈晓越.探讨TP与TAC方案对不同BRCA1表现型三阴性乳腺癌的临床疗效.[J].中南医学科学杂志.,2018,(5):491-494. |
| 探讨TP与TAC方案对不同BRCA1表现型三阴性乳腺癌的临床疗效 |
| Clinical efficacy of TP and TAC chemotherapy on triple negative breast cancer with BRCA1 negative expression |
| 投稿时间：2018-04-10 修订日期：2018-06-10 |
| DOI：10.15972/j.cnki.43-1509/r.2018.05.011 |
| 中文关键词: 可手术三阴性乳腺癌 多西他赛 卡铂 新辅助化疗 |
| 英文关键词:surgical tri-negative breast cancer docetaxe carboplatin neoadjuvant chemotherapy |
| 基金项目: |
|
| 摘要点击次数: 560 |
| 全文下载次数: 460 |
| 中文摘要: |
| 本研究旨在探讨多西他赛联合卡铂(TP)与多西他赛联合多柔比星与环磷酰胺(TAC)两种新辅助化疗对可手术三阴性乳腺癌的临床疗效以及BRCA1基因表达差异的疗效对比并进行探讨,选取62例三阴性乳腺癌患者作为研究对象,采用回顾性分析的方法,把入选病例分为TP组与TAC组,其中TP组患者采取多西他赛联合卡铂进行治疗,TAC组患者接受多西他赛联合多柔比星与环磷酰胺进行治疗,对两组患者的临床疗效以及与BRCA1基因阴性表达患者的总生存期与无进展生存时间关系进行对比分析。结果表明TP组近期临床疗效显著好于TAC组,同时TP组毒副作用较轻且两组之间具有显著性差异(P＜0.05)；BRCA1表达为阴性的患者接受TP化疗生存期以及生存质量显著提高,因此本研究认为多西他赛联合卡铂化疗对三阴性乳腺癌的临床疗效较好且无严重不良反应,同时BRCA1阴性的患者效果显著好于阳性患者,值得临床推广. |
| 英文摘要: |
| The purpose of this study was to investigate the clinical efficacy of docetaxel combined with carboplatin (TP) and docetaxel combined with doxorubicin and cyclophosphamide (TAC) for operable triple-negative breast cancer and compare the efficacy of differential BRCA1 gene expression. Sixty-two patients with triple-negative breast cancer were selected as study subjects, which were divided into TP group and TAC group by retrospective analysis. Docetaxel combined with carboplatin was used to treat TP group, TAC group received docetaxel combined with doxorubicin and cyclophosphamide for treatment. The clinical efficacy, and the relationship between overall survival and progression-free survival of patients with negative BRCA1 gene expression were compared. The results showed that the clinical efficacy of TP group was significantly better than that of TAC group and TP group had less toxic and side effects, there was a significant difference between the two groups (P<0.05). Patients with BRCA1 negative were treated with TP chemotherapy for survival and survival quality is significantly improved. Therefore, this study believes that docetaxel combined with carboplatin chemotherapy has good clinical efficacy and no serious adverse reactions to triple-negative breast cancer. At the same time, patients with negative BRCA1 are more effective than positive patients and are worthy of clinical promotion. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |